Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xevinapant plus chemoradiotherapy vs placebo in locally advanced head and neck squamous cell carcinoma
CTR20211994Phase 3Terminated
- Sponsor
- Debiopharm
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of xevinapant in head and neck squamous cell carcinoma (HNSCC), sponsored by Debiopharm. Started Aug 2021; status: terminated.
02
Drugs
xevinapant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20211994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211994.